PubMed Trending Research Digest — October 21, 2026
A curated digest of 93 trending PubMed articles, automatically categorised and summarised across 15 research areas.
Jump to category
PubMed Trending Research Digest — October 21, 2026
Automated digest · 93 articles · 15 research areas · October 21, 2026
Overview
This week’s digest is dominated by translational immunology and precision oncology: multiple studies refine how immune therapies work (or fail) in real patients and in models. In cancer, work spans checkpoint therapy durability (e.g., pembrolizumab in biliary tract cancer), immune-toxicity risk stratification in combination checkpoint regimens, and attempts to modulate CAR-T toxicity pathways—highlighting both promise and caution. At the same time, mechanistic tumor immunology is getting more granular: spatial immune niches in ANCA-associated kidney injury, MAIT-cell behavior in gastrointestinal cancers, and dendritic-cell subset control of tissue-resident memory-like CD8 T cells all point toward therapies that are increasingly “circuit- and context-specific,” not just target-specific.
A second major theme is biomarkers and risk stratification—often using “omics” or simple measurable surrogates—to move earlier detection and better matching of treatment. Examples include plasma proteomics for incident ALS and heart failure risk, CSF biomarker panels for ALS diagnosis/prognosis, metabolomics and microbiome–bile acid pathways for sex-specific liver-disease protection, and transcriptomic signatures predicting poor response to CD19 CAR T-cell therapy. In cardiometabolic and public-health arenas, modeling and cohort studies quantify how policy or physiological indices (e.g., HBV vaccination schedule changes, atherogenic-frailty index trajectories) translate into future disease burden.
Finally, several papers emphasize mechanistic biology that can become therapeutic leverage: epigenetic control (LSD1 in meiosis, EZH1/2 inhibition in HTLV-1 ocular inflammation, Polycomb mark timing), metabolic and inflammatory signaling axes (OCTN2–pyrin inflammasome, ABCA1-dependent cholesterol handling in Parkinson’s disease), and even new tools for measurement (wireless cortex-wide calcium imaging, mechanotransduction biosensors, and improved HSC niche detection). Across these diverse areas, the through-line is the same: better mechanistic resolution and better measurement are converging to improve prediction, durability, and safety of interventions.
Neurodegenerative disease therapeutics & biomarkers
Dysregulated cholesterol trafficking through ABCA1 drives neurodegeneration in Parkinson’s disease.
This study investigated how ATP-binding cassette transporter A1 (ABCA1)-mediated cholesterol trafficking contributes to neurodegeneration in Parkinson’s disease using postmortem human substantia nigra/striatal analyses and a PD mouse model, with mechanistic experiments in astrocytes and neurons. ABCA1 expression was elevated in PD, astrocytic ABCA1 drove excessive cholesterol efflux that led to neuronal cholesterol overload, and neuronal ABCA1 localized to lysosomes to facilitate cholesterol import. These findings identify ABCA1-dependent cholesterol handling as a mechanistic driver and potential therapeutic target for PD.
Ma FX, Zhao XX, Wang XX et al. · Nature neuroscience · (2026) · View on PubMed ↗
Plasma Proteomic Signatures Predict Incident Amyotrophic Lateral Sclerosis: A Prospective Study Stratified by C9orf72 Expansion.
This prospective UK Biobank study used Olink Explore plasma proteomics (2920 proteins) and Cox proportional hazards modeling to identify blood protein signatures predicting incident amyotrophic lateral sclerosis (ALS), stratified by C9orf72 expansion status. The key finding is that specific plasma proteomic patterns were associated with future ALS risk, enabling risk stratification prior to clinical onset. Clinically, this supports plasma proteomics as a route to earlier ALS detection and mechanistic insight, particularly when considering C9orf72 genetic background.
Su WM, Duan QQ, Zhang N et al. · Journal of cachexia, sarcopenia and muscle · (2026) · View on PubMed ↗
Cerebrospinal fluid amyloid and neurodegeneration biomarkers in the diagnosis and prognosis of amyotrophic lateral sclerosis: a multicohort observational study.
This multicohort observational study measured cerebrospinal fluid (CSF) biomarkers—neurofilament light chain (NfL), amyloid-β peptides, phosphorylated tau (pTau181/pTau217), and GFAP—in 264 patients with ALS and 164 disease controls to assess diagnostic and prognostic value and the impact of Alzheimer’s disease co-pathology. The study found that CSF amyloid and neurodegeneration markers can complement NfL in ALS diagnosis/prognosis, including in individuals with intermediate NfL values using a two-step diagnostic approach. This could improve clinical biomarker panels for ALS and clarify how AD-like pathology modifies disease progression.
Obara K, Janelidze S, Ito D et al. · EBioMedicine · (2026) · View on PubMed ↗
Differential Trajectories of Brain Atrophy in Multiple Sclerosis, MOGAD, and AQP4 + NMOSD: The Role of Disease Activity in MOGAD.
This longitudinal neuroimaging study compared brain atrophy trajectories across multiple sclerosis (MS), MOG antibody-associated disease (MOGAD), and aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4+NMOSD), focusing on how disease activity relates to atrophy in MOGAD. The key finding is that atrophy progression differs by disease type and that, in MOGAD, brain atrophy trajectories are linked to disease activity. This improves understanding of tissue injury mechanisms across inflammatory demyelinating disorders and may guide monitoring strategies.
Cortese R, Bianchi A, de Mauro A et al. · Neurology · (2026) · View on PubMed ↗
Exercise promotes lipophagy and mitigates cognitive impairment in Alzheimer’s disease through downregulating microglial TMEM9.
This preclinical study tested whether a three-month exercise intervention in 5×FAD transgenic mice improves Alzheimer’s disease–related cognitive and emotional phenotypes and whether this involves microglial TMEM9 regulation. Exercise promoted lipophagy, reduced lipid droplet accumulation, and mitigated cognitive impairment, with mechanistic evidence linking these effects to downregulation of microglial TMEM9. The findings are significant because they suggest a modifiable lifestyle intervention and a specific microglial target (TMEM9) for reducing AD pathology and cognitive decline.
Zhang L, Li S, Ma X et al. · Translational neurodegeneration · (2026) · View on PubMed ↗ · Free PDF ↗
Imaging nanoscopic co-assemblies of α-synuclein and Tau in human samples.
This study developed and applied a modified single-molecule pull-down (SiMPull) assay to image and quantify nanoscopic co-assemblies of α-synuclein (αS) and Tau in human samples, including post-mortem brain tissue homogenates and biofluids. αS–Tau co-assemblies were abundant across matrices and accounted for ~10–70% of total αS aggregates in both Parkinson’s disease (PD) and control samples, with soluble brain fractions from controls showing higher Proteinase K (PK) resistance. These findings suggest that αS–Tau co-assembly is a widespread molecular feature in PD biology and that co-assembly properties (e.g., protease resistance) may help refine biomarker or mechanistic models.
Zhang YP, Wallis A, Bertroli CO et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗
Huntington’s disease clinical trials update: August 2026.
This article updates Huntington’s disease therapeutic developments, focusing on clinical trials in people with Huntington’s disease, including the first-in-human phase I study of the allele-selective antisense oligonucleotide RG6496 (Hoffmann-La Roche) and phase III efficacy trials of votoplam (INVEST-HD) and pridopidine (PRECISE-HD). It reports that POINT-HD was launched and then discontinued, RG6496 entered early human testing to selectively lower mutant huntingtin while largely preserving wild-type huntingtin, and two phase III programs were launched to evaluate votoplam and pridopidine. These pipeline updates are clinically significant because they indicate which disease-modifying strategies (antisense lowering of mutant huntingtin and symptomatic/other pathway modulation via votoplam or pridopidine) are progressing toward efficacy assessment.
Farag M, Kinyomi O, Tabrizi SJ et al. · Journal of Huntington’s disease · (2026) · View on PubMed ↗ · Free PDF ↗
Cancer immunotherapy (checkpoint, CAR-T, bispecific) & toxicity
Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer: longer-term follow-up from the randomised, double-blind, placebo-controlled, phase 3 KEYNOTE-966 trial.
This report provides longer-term follow-up of the randomized, double-blind, placebo-controlled phase 3 KEYNOTE-966 trial evaluating pembrolizumab plus gemcitabine and cisplatin versus placebo plus gemcitabine and cisplatin in adults with previously untreated advanced biliary tract cancer. At median follow-up of 36.6 months, pembrolizumab maintained overall survival benefit without new safety signals (final details truncated). The extended results strengthen the clinical evidence for pembrolizumab-based first-line therapy in advanced biliary tract cancer.
Ueno M, Yoo C, Ren Z et al. · EClinicalMedicine · (2026) · View on PubMed ↗ · Free PDF ↗
Impact of Organ-Specific Severe Immune-Related Adverse Events on Long-Term Survival and Treatment Transitions in Metastatic Renal Cell Carcinoma: A 5-Year Multicenter Multistate Analysis.
This 5-year multicenter multistate analysis studied long-term survival and treatment transitions in 63 patients with metastatic renal cell carcinoma treated with ipilimumab plus nivolumab, stratified by immune-related adverse event (irAE) organ involvement and severity. Severe non-endocrine irAEs were evaluated as a temporally distinct and prognostically unfavorable phenotype compared with no irAE and severe endocrine irAE categories. Scientifically and clinically, the work supports using irAE severity and organ specificity to better predict outcomes and guide longitudinal management in combination immune checkpoint inhibitor therapy.
Tasaki Y, Sato K, Hamamoto S et al. · Cancer medicine · (2026) · View on PubMed ↗ · Free PDF ↗
Prophylactic IFN-γ blockade drives axi-cel expansion without preventing refractory toxicities: caution against pre-emptive use.
This open-label phase 2 trial evaluated prophylactic IFN-γ blockade using emapalumab given one day before axicabtagene ciloleucel (axi-cel) in patients with relapsed or refractory large B-cell lymphoma (LBCL). The key finding from the first two reported patients was that pre-emptive emapalumab did not prevent refractory toxicities and was associated with high-grade ICANS and overlapping CRS/immune effector cell-associated neurotoxicity syndrome (ICANS) toxicities. This is clinically important because it cautions against routine pre-emptive IFN-γ blockade as a toxicity-mitigation strategy for axi-cel, emphasizing the need for safer approaches.
Blumenberg V, Bozym DJ, King M et al. · Blood cancer discovery · (2026) · View on PubMed ↗
Cancer targeted therapy & molecular mechanisms
Study protocol of a prospective, non-interventional cohort study evaluating the benefits of transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma receiving first-line atezolizumab plus bevacizumab (NISTIPS TRITICC-4, IKF092).
This prospective, non-interventional cohort study (NISTIPS TRITICC-4, IKF092) evaluated whether transjugular intrahepatic portosystemic shunt (TIPS) improves outcomes in patients with hepatocellular carcinoma receiving first-line atezolizumab plus bevacizumab, with emphasis on clinically significant portal hypertension and cirrhosis-related complications. The abstract describes the rationale that TIPS lowers portal pressure and may enable continuation of immunotherapy despite bevacizumab-associated bleeding risk, but it does not provide results. If effective, TIPS could become a strategy to reduce portal-hypertension complications and improve treatment feasibility and outcomes for HCC patients on atezolizumab–bevacizumab.
Angendohr C, Weigel C, Kunstein A et al. · Future oncology (London, England) · (2026) · View on PubMed ↗
Association of Circulating Eosinophils With Systemic Immune Activation and Reduced Recurrence in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
This study evaluated whether circulating eosinophil counts predict systemic immune activation and reduced recurrence in hormone receptor-positive/HER2-negative breast cancer by analyzing preoperative eosinophils in a discovery cohort (N=472) and validating in a large propensity-score–weighted cohort (N=23,170), including integration with 21-gene recurrence scores (n=2,973). The key finding is that higher circulating eosinophils were associated with systemic immune activation and lower recurrence risk in this patient population. Clinically, eosinophil count could serve as a simple, noninvasive biomarker to refine recurrence risk alongside genomic assays.
Li ZQ, Wu SY, Ge LP et al. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · (2026) · View on PubMed ↗
Androgen Synthesis Inhibitors vs Androgen Receptor Inhibitors and Survival in Metastatic Hormone-Sensitive Prostate Cancer.
This retrospective cohort study compared outcomes of androgen deprivation therapy intensification with androgen synthesis inhibitors (ASIs) versus next-generation androgen receptor inhibitors (ARIs) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated in community or academic practice settings. ASI- and ARI-based intensification strategies were associated with different clinical outcomes over a median follow-up of 25.6 months (details truncated in the abstract). The work helps guide real-world selection between ASIs and ARIs in mHSPC where head-to-head randomized trials are limited.
Gebrael G, Jo Y, Nandakumar V et al. · JAMA network open · (2026) · View on PubMed ↗
PRAME Augments K63-Linked Ubiquitination and Stabilization of METTL3 to Promote Lung Adenocarcinoma Metastasis.
This study investigated how the cancer-testis antigen PRAME promotes lung adenocarcinoma (LUAD) metastasis by regulating the m6A methyltransferase METTL3. PRAME directly interacted with METTL3 and promoted K63-linked ubiquitination at METTL3 lysine 235, stabilizing METTL3 and enhancing downstream pro-metastatic signaling via METTL3/METTL14 complex formation (with additional partners truncated). The mechanism links PRAME to post-translational control of METTL3, identifying a potential therapeutic axis for preventing LUAD metastasis.
Yang X, Xu X, Zhang Y et al. · MedComm · (2026) · View on PubMed ↗
Long-term efficacy, clinical outcomes, and safety of vimseltinib in patients with tenosynovial giant cell tumor: results from the MOTION phase 3 trial.
This article reports long-term efficacy, clinical outcomes, and safety of vimseltinib, an oral CSF1 receptor switch-control tyrosine kinase inhibitor, in patients with tenosynovial giant cell tumor (TGCT) from the MOTION phase 3 trial. In patients with more than 2 years of follow-up, vimseltinib continued to show sustained antitumor activity and clinical benefit with safety outcomes tracked over extended exposure (specific results truncated). The long-term data further establish vimseltinib’s role for durable management of CSF1-driven TGCT.
Bhadri V, Gelderblom H, Stacchiotti S et al. · The oncologist · (2026) · View on PubMed ↗ · Free PDF ↗
Endogenous replication stress creates a unique therapeutic window for ALC1 targeting.
This study investigated how endogenous replication stress creates a therapeutic vulnerability for targeting ALC1 in serous ovarian cancer models. The authors showed that loss of the chromatin remodeler ALC1 sensitizes ovarian cancer cells, xenografts, and patient-derived models to PARP inhibitors (PARPi) across both homologous recombination deficiency (HRD) and CCNE1-amplified contexts, using ALC1 depletion as the sensitizing strategy. The findings are significant because they suggest a potential way to expand PARPi benefit to otherwise intractable CCNE1-amplified tumors while addressing resistance limitations.
Aubuchon LN, Wong DH, Greenberg SF et al. · EMBO reports · (2026) · View on PubMed ↗ · Free PDF ↗
Rare prostate cancer histologies: detection, characteristics and treatment.
This narrative review summarized rare prostate cancer histologies—including mucinous adenocarcinoma, intraductal carcinoma, ductal adenocarcinoma, neuroendocrine prostate cancer (including treatment-emergent small-cell carcinoma), sarcomatoid carcinoma, and basal cell carcinoma—focusing on detection, characteristics, and treatment. The authors emphasized that these subtypes collectively account for <5% of prostate cancers but may be underdetected due to sampling limitations rather than true rarity, and they highlighted distinct clinical and molecular features compared with acinar adenocarcinoma. The review is significant because it supports improved recognition and subtype-specific management strategies for uncommon but clinically important prostate cancer variants.
Melão BVLA, Jardim DL, Li R et al. · Nature reviews. Urology · (2026) · View on PubMed ↗
Targeting oncogenic SOX2 condensates suppresses squamous cell carcinoma progression.
This preclinical cancer study investigated whether targeting oncogenic SOX2 condensates suppresses squamous cell carcinoma progression across esophageal, head and neck, and lung squamous cell carcinomas. The key finding is that SOX2 condensates—promoted by activation domain 1 (AD1)—enhance SOX2 chromatin occupancy, H3K27ac enrichment, and chromatin interactions at oncogenic loci such as FGFR2, thereby promoting tumor progression. This is clinically significant because it identifies SOX2 condensate biology as a potential therapeutic vulnerability in SCCs.
Luan S, Sun J, Dong Y et al. · Cell reports. Medicine · (2026) · View on PubMed ↗ · Free PDF ↗
Isobavachalcone targets deubiquitinase OTUB1 to induce PD-L1 degradation and enhances antitumor immunity.
This study used small-molecule screening and mechanistic assays to test whether isobavachalcone (IBC) can modulate PD-L1 homeostasis by targeting the deubiquitinase OTUB1 in tumor models. The key finding is that IBC binds OTUB1 at His217, suppresses its deubiquitinase activity, increases K48-linked polyubiquitination of PD-L1, and promotes proteasome-dependent PD-L1 degradation, enhancing CD8+ T cell cytotoxicity. This is significant because it suggests a potential strategy to improve antitumor immunity by degrading PD-L1 through an OTUB1-directed mechanism.
Zhang Q, Li S, Xu M et al. · Cell reports. Medicine · (2026) · View on PubMed ↗ · Free PDF ↗
Biomarker-guided treatment strategies for patients with gliomas in clinical practice.
This review summarized biomarker-guided treatment strategies for glioma patients in clinical practice, focusing on how molecular markers can enable targeted therapy selection. It emphasizes that while glioblastoma has had limited targeted-therapy success, biomarker-driven approaches are already changing practice in non-glioblastoma gliomas, exemplified by IDH-mutant inhibition with vorasidenib. The significance is that integrating biomarkers into clinical decision-making can improve patient selection for targeted therapies and guide future trial designs in glioma.
Le Rhun E, Mellinghoff IK, Weiss T et al. · Neuro-oncology · (2026) · View on PubMed ↗
Cancer microenvironment & tumor biology (CAF/DC/TME, mechanics, immune niches)
Single‑cell and spatial transcriptomics in chronic lung disease: cellular heterogeneity and molecular mechanisms in IPF and COPD.
This study applied single-cell RNA sequencing and spatial transcriptomics to characterize cellular heterogeneity, tissue architecture, and intercellular communication in chronic lung disease, focusing on idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD). The authors reported disease-specific remodeling patterns across epithelial, stromal, immune, and endothelial compartments and used the spatial context to infer molecular mechanisms underlying persistent injury and maladaptive repair. The results are significant for identifying cell-type–resolved pathways and spatially organized targets that could guide precision therapies for IPF and COPD.
Huang X, Qu F, Luo Q et al. · Respiratory research · (2026) · View on PubMed ↗ · Free PDF ↗
Distinct migratory dendritic cell subsets cooperate to prime tissue-resident memory-like CD8⁺ T cells in mouse tumors.
This study investigated how distinct migratory dendritic cell (DC) subsets cooperate to prime tumor-infiltrating tissue-resident memory-like CD8+ T cells in a mouse lung adenocarcinoma model (KrasG12D, p53-/-). Selective ablation showed that XCR1+ DC1s were required for generating tumor-infiltrating effector and exhausted CD8+ T cells, while both migratory DC1s and migratory DC2s contributed to specifying CD103+CD69+ TRM-like CD8+ T cells. The results define DC subset-specific roles in TRM-like CD8+ T cell programming, informing how to design immunotherapies that promote durable, tissue-resident anti-tumor immunity.
Vaudiau N, Bourdely P, Semitekolou M et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗
Cytokine context shapes antigen-presenting and matrix-producing states of cancer-associated fibroblasts.
This study used integrated single-cell and spatial transcriptomic profiling across four cancer types to determine how cytokine context shapes cancer-associated fibroblast (CAF) states in the tumor microenvironment. It identified two immunomodulatory CAF states—antigen-presenting CAFs (apCAFs) and matrix-producing CAFs (mCAFs)—where apCAFs correlated with enhanced anti-tumor immune features and favorable prognosis, while mCAFs were associated with immunosuppressive characteristics. These results connect cytokine-driven plasticity to CAF functional programs, offering a framework for targeting specific CAF states to improve anti-tumor immunity.
Song F, Chen Q, Huang D et al. · Signal transduction and targeted therapy · (2026) · View on PubMed ↗ · Free PDF ↗
MAIT cells in gastrointestinal cancer: immunity to therapy.
This article is a mechanistic review of MAIT (mucosal-associated invariant T) cells in gastrointestinal cancers, focusing on how MAIT cells recognize microbial-derived metabolites presented by MR1 and how they function within the tumor microenvironment. It highlights that MAIT cells can mediate antitumor immunity but often become functionally exhausted, with roles shaped by microbiome and immune signaling context across GI malignancies. The synthesis is significant for guiding future therapeutic strategies that modulate MAIT cell activity to improve GI cancer treatment responses.
Li YR, Chen Y, Yeh S et al. · Trends in cancer · (2026) · View on PubMed ↗ · Free PDF ↗
Spatial Transcriptomics on a Diverse Pancreatic Cancer Cohort Reveals Race-Related Differences in Tumor Subtypes and Immune Microenvironments.
This study compared Black African American (BAA) versus Non-African American (NAA) pancreatic ductal adenocarcinoma (PDAC) using whole exome sequencing, spatial transcriptomics, and spatial proteomics in a diverse multi-omics cohort. The key finding was that BAA PDAC tumors showed race-associated differences in tumor subtypes and immune microenvironments despite whole exome sequencing showing no significant differences in driver mutations between groups. This is clinically significant because it suggests that ancestry-linked microenvironmental and transcriptional programs—not driver mutation differences—may contribute to PDAC disparities and could inform more tailored biomarker and therapeutic approaches.
Wu Y, Sålas-Escabillas DJ, Xie A et al. · Cancer research · (2026) · View on PubMed ↗
Mechanical Stress Induces Nuclear Envelope Rupture in Melanoma Cells to Reorganize Tumor-Stromal Interactions.
This study investigated how recurrent macroscopic mechanical stress affects melanoma cells and tumor-stromal interactions, focusing on nuclear envelope rupture as a mechanistic link. The key finding was that mechanical stress induced nuclear envelope rupture, which then drove spatial reorganization and fibroblast subtype changes within the tumor microenvironment. This is significant because it identifies a physical-to-cellular mechanism that may help explain how external stressors promote melanoma progression and alter stromal composition relevant to therapy resistance.
Kim H, Kim W, Kim M et al. · Cancer research · (2026) · View on PubMed ↗
Hematologic malignancies (leukemia/lymphoma/myeloma) trials & biomarkers
Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy.
This translational study profiled 423 tumor samples from newly diagnosed multiple myeloma patients in the MIDAS cohort to identify molecular predictors of measurable residual disease (MRD) after quadruplet induction therapy. Using integrated genomic, transcriptomic, and epigenomic profiling, the authors associated molecular heterogeneity with postinduction MRD-negativity following isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd). The findings are clinically significant because they aim to enable earlier risk stratification and more personalized treatment decisions in NDMM.
Magrangeas F, Cherkaoui M, Bessonneau-Gaborit V et al. · Nature medicine · (2026) · View on PubMed ↗ · Free PDF ↗
Treatment patterns and outcomes for second-line therapy in large B-cell lymphoma: results from the LEO CReWE study.
This study analyzed real-world treatment patterns and outcomes for second-line (2L) therapy in relapsed/refractory large B-cell lymphoma (R/R LBCL) using the LEO CReWE cohort of 1504 patients treated from 2002–2022. In this cohort, 64% received chemoimmunotherapy at 2L, with planned ASCT and/or CAR-T in 65% (31% ultimately receiving ASCT and 6% CAR-T), and complete response rates at 2L varied from 24% with lenalidomide-based regimens to 49% with CAR-T. Clinically, these data quantify how 2L regimen selection and subsequent use of ASCT/CAR-T relate to response rates, supporting evidence-informed sequencing strategies in R/R LBCL.
Koff JL, Larson MC, Cohen JB et al. · Blood cancer journal · (2026) · View on PubMed ↗ · Free PDF ↗
Transcriptome Analysis Identifies a Myeloid-Like Signature in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Patients With Poor Response to CD19 Chimeric Antigen Receptor T Cell Therapy.
This study analyzed pre-treatment bone marrow transcriptomes and genetic alterations in 15 relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) patients enrolled in a phase II trial of CD19 CAR T-cell therapy (NCT04684147), comparing 8 good responders versus 7 poor responders at a 3-month landmark. Transcriptome analysis identified a myeloid-like gene expression signature associated with poor response to CD19 CAR T therapy. The results suggest a potential intrinsic leukemia biomarker for stratifying patients and anticipating resistance to CAR T treatment.
Wang S, Liu W, Wang Y et al. · Cancer medicine · (2026) · View on PubMed ↗ · Free PDF ↗
Combined ATR and mitotic inhibition is effective against MYCN-amplified neuroblastoma.
This study used high-throughput combinatorial drug screening in MYCN-amplified human neuroblastoma (NB) tumoroids to test whether ATR inhibition combined with mitotic inhibition would synergize while limiting toxicity. The key finding was that combined ATR and mitotic inhibition produced effective synergy against MYCN-amplified NB, identified through dose-response matrices across multiple NB tumoroids and CD34+ cord blood cells and prioritized using synergy scoring and machine learning. This supports a mechanism-orthogonal therapeutic strategy for high-risk MYCN-amplified pediatric NB that may improve efficacy while addressing dose-dependent toxicity constraints of mitotic inhibitors.
Radke K, Hansson K, Chattopadhyay S et al. · Molecular cancer therapeutics · (2026) · View on PubMed ↗ · Free PDF ↗
A randomized phase 2 study combining midostaurin, low-dose cytarabine and venetoclax in newly diagnosed AML ≥60 years.
This randomized phase 2 trial studied adding the FLT3 inhibitor midostaurin to low-dose cytarabine plus venetoclax in newly diagnosed AML patients aged ≥60 years who were unfit for intensive chemotherapy, as part of the INTERVENE study. The abstract indicates the rationale that FLT3-ITD–driven resistance may be overcome by incorporating midostaurin into standard venetoclax-based low-intensity therapy, while prior FLT3 inhibitor additions have not improved survival without dose-reduction–related marrow toxicity. If efficacy and tolerability are confirmed, this regimen could provide a more effective, mechanism-targeted option for older FLT3-ITD AML patients receiving low-intensity venetoclax combinations.
Chua CC, Hsu WH, Enjeti AK et al. · Blood · (2026) · View on PubMed ↗
Epigenetics & chromatin regulation (including LSD1/Polycomb/acetylation/m6A)
Regulatable in vivo gene expression via adaptamers.
This preclinical study developed an ADAR-modulatable aptamer (“adaptamer”), a compact (<120 bp) RNA switch that uses endogenous ADAR-mediated RNA editing to reversibly regulate transgene expression in vivo in response to a small molecule. The key finding is that ligand binding stabilizes a double-stranded RNA structure that recruits ADAR to convert a stop codon into a sense codon, restoring downstream protein translation without RNA cleavage. This provides a potentially more translatable, controllable inducible gene-expression platform for safer in vivo gene therapy.
Bryant J, Herron L, Doctor Y et al. · Molecular cell · (2026) · View on PubMed ↗
Transient ATM inhibition enhances knock-in efficiency in hematopoietic stem cells by attenuating the DNA damage response.
This study tested whether transient inhibition of ATM kinase improves CRISPR/Cas9 knock-in (KI) efficiency in mouse hematopoietic stem cells (HSCs) edited with Cas9 RNP and AAV donor DNA. Transient ATM inhibition suppressed aberrant Cas9–AAV–induced ATM activation and downstream DNA damage response, reduced p53-dependent apoptosis, and increased survival of KI HSCs. The results support ATM-targeted modulation as a practical way to enhance genome editing outcomes in HSC-based therapies.
Natsagdorj ME, Hara H, Iida K et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗
Dual impact of EZH1/2-targeted therapy in HTLV-1-associated inflammation: Direct and indirect mechanisms.
This study examined direct and indirect mechanisms by which dual EZH1/2 inhibition could modulate HTLV-1-associated ocular inflammation, using in vitro co-culture and infection models. HTLV-1 increased EZH1/EZH2 expression and H3K27me3 in retinal pigment epithelial cells, and treatment with the dual EZH1/2 inhibitor valemetostat reduced H3K27me3 with limited effects on viability and model-dependent changes in proviral load. These findings support EZH1/2-targeted epigenetic therapy as a potential strategy to treat HTLV-1-driven inflammation such as uveitis.
Zou Y, Kamoi K, Yang M et al. · iScience · (2026) · View on PubMed ↗ · Free PDF ↗
Establishing Polycomb regulatory landscapes in human early development.
This study examined how Polycomb group (PcG) repression is established during human early development by profiling H2Aub dynamics from human gametes through blastocysts. The authors found that H2Aub emerges in GC-rich regions as early as the two-cell stage, accumulates across active and inactive genes, and later culminates at PcG targets, while H3K27me3 shows weak correlation with H2Aub in oocytes and early embryos. The work is significant because it clarifies the timing and coordination of PcG chromatin marks in human preimplantation development, informing models of early gene regulation.
Hu X, Zhang C, Liu B et al. · Nature genetics · (2026) · View on PubMed ↗
A ubiquitin carboxyl-terminal hydrolase facilitates H2A.Z removal in response to phosphate starvation.
This study investigated how the plant ubiquitin carboxyl-terminal hydrolase UCH2 regulates histone variant H2A.Z dynamics during phosphate starvation in response to Pi deficiency. UCH2 was recruited by PHR1 to Pi starvation-induced (PSI) gene promoters, where UCH2 deubiquitinated H2A.Z to reduce H2A.Z occupancy at these promoters and promote PSI gene activation, while loss of UCH2 impaired H2A.Z removal and PSI induction. Scientifically, it links a specific deubiquitinase (UCH2) to stress-responsive chromatin remodeling of H2A.Z, providing a mechanistic route to control phosphate-starvation transcription in plants.
Meng F, Xiao X, Ma G et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗
Epigenetics in development, disease, and therapy: from mechanisms to clinical interventions.
This Science China Life Sciences review synthesized evidence on epigenetic mechanisms—including DNA methylation, histone modifications, chromatin remodeling, and non-coding RNAs—and how they drive development, aging, and disease. It also summarizes emerging therapeutic approaches that target epigenetic regulation for clinical intervention. The significance is that it provides a mechanistic and translational framework for designing and prioritizing epigenetic therapies across multiple disease areas.
Ren Y, Yang L, Fei B et al. · Science China. Life sciences · (2026) · View on PubMed ↗ · Free PDF ↗
Metabolism, microbiome–host axes & metabolic disease
Spatiotemporal metabolic networks in a preclinical model of pancreatic cancer and associated cachexia.
This study characterized spatiotemporal metabolic networks across tissues in a preclinical mouse model that recapitulates longitudinal human pancreatic cancer cachexia. Metabolomic profiling across pancreas, interstitial fluid, plasma, liver, adipose tissue, and skeletal muscle revealed tissue-specific metabolite trajectories across pre-, early-, and late-stage cachexia, including marked lipid enrichment in tumor interstitial fluid, and mathematical modeling identified candidate metabolic drivers of cachexia progression. The work provides a systems-level map of cachexia metabolism that can guide biomarker discovery and therapeutic targeting of metabolic pathways in pancreatic cancer.
Majem B, Lee MS, Shin KC et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗
Miro1 mediates skeletal muscle insulin resistance in type 2 diabetes.
This study examined the role of mitochondrial Rho GTPase 1 (Miro1) in skeletal muscle insulin resistance in type 2 diabetes (T2D) using both a cross-sectional clinical analysis and mouse T2D models. Miro1 accumulated in skeletal muscle of patients with obesity and T2D and was replicated in mouse models, and this accumulation was attributed to inadequate insulin-mediated interaction between AKT and Miro1 at the outer mitochondrial membrane. These findings implicate the AKT–Miro1 axis in mitochondrial dysfunction driving insulin resistance, highlighting Miro1 as a potential mechanistic target for improving metabolic control in T2D.
Heintz EC, Dantas WS, Taylor AL et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗
An acetylcholine-inhibited sleep-active hippocampal interneuron orchestrates memory consolidation.
This mouse and macrophage study investigated how the pyrin inflammasome senses extracellular L-carnitine uptake mediated by the high-affinity transporter OCTN2, using LPS-challenged mice and LPS-primed murine and human macrophages. The key finding is that extracellular L-carnitine represses mevalonate synthesis and triggers pyrin inflammasome activation downstream of OCTN2-mediated import, linking muscle injury or dietary L-carnitine to inflammasome-driven inflammation. This is clinically significant because it mechanistically connects red-meat/L-carnitine exposure and muscle injury to chronic inflammatory pathways and identifies OCTN2–pyrin signaling as a potential therapeutic axis.
Feng Y, Dai Q, Fei X et al. · Neuron · (2026) · View on PubMed ↗
A microbiome-bile acid axis mediates protection from chronic liver disease in females.
This study used a large-scale metabolomics database (9,254 individuals) and mechanistic experiments to define how a microbiome–bile acid axis mediates sex-based protection from chronic liver disease in females. The key finding is that estrogen-enriched intestinal microbial communities produce the bile acid isoursodeoxycholic acid (isoUDCA), which promotes nuclear SREBP2 accumulation and upregulates STARD4 to drive hepatoprotection. This is significant because it provides a sex-specific, microbiome-derived molecular pathway that could be targeted to prevent or slow chronic liver disease progression.
Li M, Kuang J, Chen T et al. · Cell · (2026) · View on PubMed ↗ · Free PDF ↗
The conserved NUS-1/DHDDS-1 complex links N-glycosylation to lipid and lysosomal homeostasis in C. elegans.
This study used the nematode Caenorhabditis elegans to define how the conserved NUS-1/DHDDS-1 (cis-prenyltransferase) complex regulates N-glycosylation and thereby lipid and lysosomal homeostasis. Loss of NUS-1/DHDDS-1 caused endoplasmic reticulum stress, lysosomal collapse, and systemic lipopenia, mechanistically by impairing N-glycosylation of the SREBP cleavage-activating protein (SCAP) leading to its degradation. These findings link N-glycosylation to lipid/lysosomal regulation through SCAP and suggest a conserved pathway that could be relevant to metabolic and lysosomal disorders.
Gong M, Zhao W, Du Y et al. · Cell reports · (2026) · View on PubMed ↗ · Free PDF ↗
SIRT6 Activation Improves Intervertebral Disc Health in the Aging Spine.
This preclinical study tested whether systemic administration of the small-molecule SIRT6 agonist MDL-800 improves intervertebral disc health in aged mice (24-month-old), linking effects to SIRT6 activation. MDL-800 treatment improved disc morphology and reduced degeneration scores, with molecular changes including decreased H3K9 acetylation (H3K9ac), improved extracellular matrix quality, and reduced senescence markers such as p21, IL-6, TGF-β, and CCL2. These results support SIRT6 activation as a therapeutic target to slow age-related intervertebral disc degeneration and potentially reduce chronic low back pain risk.
Ramteke P, Watson B, Jagannath S et al. · Aging cell · (2026) · View on PubMed ↗ · Free PDF ↗
Cardiometabolic risk prediction & vascular disease
Radiation Vasculopathy of the Coronary Arteries: State-of-the Art Review.
This state-of-the-art review synthesized current knowledge on radiation vasculopathy of the coronary arteries (RACAD) in patients exposed to thoracic radiotherapy. The key finding is that ionizing radiation promotes endothelial dysfunction and accelerated atherosclerosis via free-radical generation and proinflammatory cascades, with RACAD risk shaped by radiotherapy dose and coronary proximity. This is clinically important because it highlights mechanistic drivers and knowledge gaps that can guide prevention, surveillance, and future therapeutic strategies for long-term survivors.
Xia J, Kim J, Sharma A et al. · Circulation · (2026) · View on PubMed ↗
A Common CD36 Variant and the Genetic Landscape of Dilated Cardiomyopathy in Individuals of African Ancestry.
This genetic association study in individuals of African ancestry compared the contribution of a common CD36 nonsense variant to dilated cardiomyopathy (DCM) risk against truncating variants in TTN and other pathogenic/likely pathogenic variants. The abstract indicates the study’s objective is to quantify how much DCM burden is attributable to the CD36 variant relative to established monogenic causes. Establishing the relative contribution of CD36 could improve genetic risk stratification and mechanistic understanding of DCM in populations with higher disease prevalence.
Challa SP, Biddinger KJ, Abramowitz SA et al. · JAMA · (2026) · View on PubMed ↗
Serum Golgi Protein 73 as a Noninvasive Marker of Hepatic Fibrosis in Chronic Hepatitis C Virus Infection.
This retrospective study evaluated serum Golgi protein 73 (GP73) as a noninvasive biomarker for hepatic fibrosis in 978 patients with chronic hepatitis C virus (HCV) infection. Using hepatic fibrosis staging based on vibration-controlled transient elastography (VCTE) cutoffs (≤7.0, 7.1–9.4, 9.5–12.4, ≥12.5 kPa corresponding to F0–F1, F2, F3, and F4), it compared GP73 with APRI and FIB-4 across fibrosis stages and assessed diagnostic performance using AUROC and DeLong tests. The significance is that GP73 could improve noninvasive fibrosis assessment in HCV, potentially reducing reliance on invasive procedures.
Chen YC, Chang YP, Bedrava J et al. · Journal of medical virology · (2026) · View on PubMed ↗ · Free PDF ↗
Associations of cumulative exposure and dynamic trajectories of the combined atherogenic-frailty index with incident cardiometabolic multimorbidity: a prospective cohort study.
This prospective cohort study examined how cumulative exposure and longitudinal trajectories of the combined atherogenic-frailty index (AIP-FI) relate to incident cardiometabolic multimorbidity (CMM) in adults aged ≥45 years without baseline CMM from CHARLS (n=4,157). It constructed AIP-FI as the product of the atherogenic index of plasma (AIP) and a 37-deficit frailty index, and evaluated associations of cumulative AIP-FI and its trajectories with subsequent CMM development. The significance is that AIP-FI may provide an early risk stratification tool by capturing both dyslipidemia-related atherogenic burden and physiological frailty.
Wu H, Song Z, Ye T et al. · Journal of global health · (2026) · View on PubMed ↗ · Free PDF ↗
Large-scale plasma proteomic profiling enhances prediction of heart failure among hypertensive individuals: prospective insights from the UK Biobank.
This prospective UK Biobank study aimed to improve prediction of heart failure (HF) among hypertensive individuals by using large-scale plasma proteomic profiling. It measured 2,911 proteins with the Olink Explore platform in 16,128 hypertensive participants without baseline HF, identified HF-associated proteins via Cox models in a training set, and built a protein risk score (PRS) using LASSO regression before validating model performance in an independent set. The significance is that proteomics-derived risk scores may detect molecularly high-risk hypertensive patients earlier than conventional clinical models.
Li M, He X, Xiao S et al. · Journal of global health · (2026) · View on PubMed ↗ · Free PDF ↗
Diabetes & endocrine interventions (including incretins, insulin tech)
Changes in Muscle Strength Following Semaglutide Treatment in Adults: A Systematic Review With Meta-Analysis of Handgrip Strength.
This systematic review and meta-analysis studied within-group changes in skeletal muscle strength (handgrip and knee extension) in adults treated with semaglutide across randomized, non-randomized, and uncontrolled before-after studies. Pooled results (primary analysis) quantified changes in handgrip strength after semaglutide, addressing whether incretin therapy alters muscle strength beyond weight loss. Clinically, the findings help determine whether semaglutide-associated weight loss carries a risk of functional muscle harm that could affect long-term outcomes.
Machado LG, Siedschlag Schmidt PH, Tasca Petroski G et al. · Diabetes, obesity & metabolism · (2026) · View on PubMed ↗ · Free PDF ↗
Weight Regain After Incretin Treatment: The Lean Mass Deficit Hypothesis and a Role for Testosterone Combination Therapy in Men.
This article evaluated the hypothesis that incretin therapy–related lean mass (especially muscle) loss contributes to weight regain and considered testosterone combination therapy in men. It frames GLP-1RA and related incretin agonists as producing substantial placebo-subtracted weight loss while potentially altering body composition in ways that could undermine long-term maintenance. The significance is that targeting muscle preservation may be necessary to reduce clinically meaningful harm and improve durability of incretin-induced weight loss.
Zitzmann M, Bosnyak Z, Jones R et al. · Diabetes, obesity & metabolism · (2026) · View on PubMed ↗ · Free PDF ↗
Foundation artificial intelligence models for health recognition by use of face photographs (FAHR-Face): a model development and validation study.
This randomized controlled trial studied the smart multiple daily injections (MDI) system versus MDI plus continuous glucose monitoring (CGM) in 143 adults with type 1 diabetes and HbA1c ≥ 8%. The key finding was that outcomes were driven by patients’ responses to smart alert prompts, with time-in-range (TIR) at 6 months as the primary endpoint assessed for non-inferiority. The study supports alert-response–based insulin action as a practical strategy to improve glycemic control in higher-HbA1c type 1 diabetes.
Haugg F, Lee G, He J et al. · The Lancet. Digital health · (2027) · View on PubMed ↗ · Free PDF ↗
Inflammation, autoimmunity & immunomodulatory strategies (RA/psoriasis/IBD/asthma)
Joint American Academy of Dermatology-Hidradenitis Suppurativa Foundation guidelines of care for the management of hidradenitis suppurativa.
This article developed joint American Academy of Dermatology–Hidradenitis Suppurativa Foundation evidence-based guidelines for managing hidradenitis suppurativa using systematic review and GRADE methodology. It provides 37 recommendations, including strong recommendations for biologics such as adalimumab, bimekizumab, infliximab, and secukinumab, and routine pain assessment. These guideline updates standardize care for patients with hidradenitis suppurativa and support evidence-based treatment selection.
Naik HB, Yeung H, Frazer-Green L et al. · Journal of the American Academy of Dermatology · (2026) · View on PubMed ↗
Monocyte surface Y RNAs potentiate innate immunity.
This study examined how Y RNAs, a family of small noncoding RNAs, localize and function on primary human monocytes and how this relates to inflammatory bowel disease (IBD) in patients and disease activity in mice. Y RNAs preferentially localized to the surface of human monocytes, were enriched on peripheral monocytes in an exploratory IBD cohort, and in vivo depletion of cell-surface Y RNAs ameliorated disease activity in a mouse model. These findings identify cell-surface Y RNAs as a monocyte innate-immunity potentiator and suggest a potential therapeutic target for IBD by modulating surface RNA signaling.
Jiang X, He W, Xu C et al. · Nature cell biology · (2026) · View on PubMed ↗
Innovative therapies in rheumatoid arthritis: CAR T cells and bispecific antibodies.
This review summarized emerging immune therapies for rheumatoid arthritis, focusing on CAR T-cell approaches and bispecific antibodies targeting pathogenic immune memory. It discusses how these therapies aim to eradicate or reprogram autoreactive immune cells to achieve more durable outcomes than conventional continuous immunomodulation. The clinical significance is framing CAR T and bispecific strategies as potential next-generation options for patients with persistent, refractory inflammatory disease.
Avouac J, Jouret M, Bitoun S et al. · The Lancet. Rheumatology · (2026) · View on PubMed ↗
Psoriasis: Which therapy for which patient, updated, part I. Focus on Psoriasis Comorbidities and Preferred Systemic Agents.
This updated clinical review evaluated how to select systemic therapy for patients with psoriasis based on comorbidity profiles, extent of disease, prior treatment response, and patient preferences, with a focus on inflammatory comorbidities and patients with a history of malignancy. The key finding is a structured, comorbidity-driven approach to choosing among preferred systemic agents for psoriasis (Part I of an updated series). This is scientifically and clinically significant because it supports more individualized treatment selection to improve outcomes while accounting for comorbidity-related risks.
Pasumarthi A, Karpoff K, Lebwohl M · Journal of the American Academy of Dermatology · (2026) · View on PubMed ↗
Updated treatment targets in inflammatory bowel disease (STRIDE-III): an initiative of the International Organization for the Study of IBD.
The STRIDE-III initiative updated inflammatory bowel disease treatment targets for Crohn’s disease and ulcerative colitis by synthesizing post-STRIDE-II evidence and incorporating surveys of IOIBD members and pediatric gastroenterologists, followed by modified Delphi consensus voting. The key finding is the publication of revised, consensus-based therapeutic targets spanning inflammatory and patient-centered outcomes for both adult and pediatric IBD care. This is significant because it provides an updated international framework to standardize treat-to-target goals and guide clinical decision-making.
Turner D, Ricciuto A, Yuval Bar-Asher S et al. · The lancet. Gastroenterology & hepatology · (2026) · View on PubMed ↗
Initiating Biologics in Atopic Dermatitis: Global Practices and Recommendations from the AMAZE Project.
The AMAZE project article surveyed 150 dermatologists across North America, Europe, and Japan to characterize real-world practices for initiating biologics in moderate-to-severe atopic dermatitis and to develop expert-informed recommendations. The key output is a set of global best-practice guidance for biologic initiation and long-term management in routine care. This is significant because it aims to standardize safe, effective biologic use and reduce variability in how clinicians implement these therapies.
Armstrong AW, Kim HJ, Pink AE et al. · Dermatology and therapy · (2026) · View on PubMed ↗ · Free PDF ↗
Immune Checkpoint Dysfunction Remodels Adaptive Immune Receptor Repertoires in CTLA-4 Insufficiency and LRBA Deficiency.
This review analyzed how immune checkpoint dysfunction affects adaptive immune receptor repertoires in patients with CTLA-4 insufficiency and LRBA deficiency using high-resolution AIRR-seq of αβ T-cell receptor and B-cell receptor repertoires. The abstract indicates that CTLA-4 and LRBA defects remodel adaptive immune receptor repertoires, with analysis including total and naïve CD4+ and CD8+ T-cell subsets. Understanding these repertoire changes is clinically significant for characterizing immune dysregulation in these inborn errors of immunity and may inform monitoring and therapeutic strategies.
Cildir G, Cildir S, Erdogan RK et al. · Clinical reviews in allergy & immunology · (2026) · View on PubMed ↗
Type 2 Inflammation in Airway Diseases: Eosinophilic Bronchiectasis as an Emerging Phenotype.
This narrative review examined eosinophilic bronchiectasis as an emerging type 2 (T2) inflammatory phenotype within airway diseases, synthesizing evidence across clinical and mechanistic studies. It highlights that eosinophilic bronchiectasis is characterized by eosinophil-driven airway inflammation and T2 immune activation, with differential responsiveness to targeted therapies compared with the traditionally neutrophil-dominated view of bronchiectasis. Clinically, recognizing this phenotype can improve patient stratification and guide selection of T2-targeted treatments in bronchiectasis.
Lombardi C, Cottini M, Menzella F et al. · Clinical reviews in allergy & immunology · (2026) · View on PubMed ↗
Positioning of Depemokimab in Uncontrolled Severe Asthma.
This article reviewed the clinical positioning of depemokimab, an ultra-long-acting anti–IL-5 monoclonal antibody, for patients with uncontrolled severe asthma. It reports that depemokimab (administered every 26 weeks) produces rapid and sustained reductions in blood eosinophils and, in phase 3 SWIFT-1 and SWIFT-2 trials, reduced the pooled annualized rate of clinically significant exacerbations by 54% versus control. The significance is that depemokimab’s dosing interval and efficacy support a practical, eosinophil-targeted strategy for reducing exacerbations and treatment burden in severe T2 asthma.
Miralles-López JC, García-Moguel I, Habernau-Mena A et al. · Journal of investigational allergology & clinical immunology · (2026) · View on PubMed ↗ · Free PDF ↗
Epitope-diverse autoantibodies induce neutrophil-epithelial niches driving kidney injury in ANCA-associated glomerulonephritis.
This study investigated how epitope-diverse autoantibodies create kidney injury niches in myeloperoxidase (MPO)-ANCA-associated glomerulonephritis, using single-cell-resolved spatial transcriptomics on treatment-naïve patient biopsies. It identified early-phase inflammatory neutrophil–epithelial niches enriched with HAVCR1+ injured proximal tubular epithelial cells, neutrophils, lymphocytes, and TREM2+ macrophages, with injured epithelial cells expressing chemokines such as CXCL6 and CXCL16. The clinical significance is that mapping these spatial immune niches clarifies how pathogenic ANCA responses localize to drive injury, potentially enabling more targeted therapeutic approaches.
Nishide M, Matsushita H, Mizuno Y et al. · The Journal of experimental medicine · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗
Long-term efficacy of lebrikizumab in treating head, neck and face involvement in patients with moderate-to-severe atopic dermatitis.
This post hoc analysis assessed long-term efficacy of lebrikizumab 250 mg every 4 weeks in adolescents (≥12 years, ≥40 kg) and adults with moderate-to-severe atopic dermatitis involving the head, neck, and face (HNF) across phase 3 trials (ADvocate 1&2, ADjoin) and targeted populations (ADmirable, ADapt). Among week 16 responders, HN outcomes were durable through 3 years, with week 152 maintenance rates of HN EASI 75 (94.8%), HN EASI 90 (82.9%), and HN EASI 100 (85.3%). This is clinically significant because it provides longer-term biologic evidence that lebrikizumab sustains HNF disease control, an area where long-term data have been limited.
Chovatiya R, de Bruin-Weller M, Alexis A et al. · The Journal of dermatological treatment · (2026) · View on PubMed ↗ · Free PDF ↗
Infectious disease & host–pathogen interactions (viruses, bacteria, parasites)
Meta-analysis of 990 EBV genomes identifies EBER2 SNP7048 and its interaction with HLA-A*11:01 driving nasopharyngeal carcinoma risk.
This study performed whole-genome sequencing of 388 EBV isolates with matched host whole-exome sequencing in a Singaporean cohort, then conducted a meta-GWAS and phylogenetic analysis across three cohorts totaling 990 EBV genomes to identify EBV genetic variants linked to nasopharyngeal carcinoma (NPC) risk. The key finding is that an EBV strain-associated variant, EBER2 SNP7048, interacts with host HLA-A*11:01 to increase NPC risk. This clarifies how specific EBV genomic features and host HLA genetics jointly shape NPC susceptibility across endemic regions.
Wang CY, Yao F, Zhang X et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗
A tunable immune-evasion function of Zika virus NS5 governs viral fitness and pathogenesis.
This study examined how Zika virus (ZIKV) nonstructural protein 5 (NS5) regulates immune evasion of type I interferon signaling in the context of STAT2 degradation, using a multistep mutational scanning approach. The authors identified a single NS5 residue, L162, that uniquely permits substitutions abolishing STAT2 degradation while preserving intrinsic viral replication fitness, thereby tuning viral fitness and pathogenesis. These findings clarify a specific NS5–STAT2 immune-evasion control point that could inform antiviral strategies targeting ZIKV interferon antagonism.
Zhang Y, Zhang Y, Liu C et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗
A host-virus arms race over FAM134B in African swine fever virus infection.
This study investigated host–virus interactions in African swine fever virus (ASFV) infection centered on FAM134B, an ER-resident cargo receptor that mediates reticulophagy. ASFV countered FAM134B-mediated restriction by using the virulence factor pMGF300-2 R encoded by the MGF300-2 R gene to bind FAM134B, recruit LC3B, and thereby disrupt FAM134B-driven lysosomal degradation of ASFV capsid proteins (p72 and pA137R) that blocks capsid assembly. The work reveals a molecular arms-race mechanism that could identify targets to enhance antiviral reticulophagy against ASFV.
Wang T, Luo R, Huang R et al. · Autophagy · (2026) · View on PubMed ↗
The brain of the female Anopheles gambiae mosquito at spatial and single-cell resolution.
This study mapped the female Anopheles gambiae brain at spatial and single-cell resolution to define cellular diversity, spatial organization, and transcriptional changes associated with life history events using single-cell and single-brain RNA sequencing. The authors did not observe expansion of specific cell populations, but they found modulation of neurotransmission in mated mosquitoes and metabolic and immune responses associated with glial and Kenyon cell populations. Scientifically, this provides a high-resolution cellular atlas linking reproductive state to brain circuit and glia-associated metabolic/immune programs, relevant to understanding mosquito behavior underlying malaria transmission.
Rossi IZ, Cassan C, Bagnoli JW et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗
A nematode-trapping fungus orchestrates polarity cues, septins, and NOX signaling for trap formation.
This study examined how the nematode-trapping fungus Arthrobotrys oligospora forms adhesive traps and establishes infection polarity, using live-cell imaging, genetics, and functional assays. It found that trap morphogenesis involves localized redirection of hyphal growth followed by site-specific hyphal fusion, while infection development transitions from isotropic infection-bulb expansion to multipolar invasive growth coordinated by polarity cues, septins, and NOX signaling. Scientifically, it delineates a signaling-and-structure program for microbial trap formation and invasion that could inform broader principles of morphogenesis and host interaction.
Kuo CY, Lin HC, Chou YZ et al. · The Journal of cell biology · (2026) · View on PubMed ↗ · Free PDF ↗
Reproductive biology, fertility & developmental epigenetics
LSD1 exerts crucial functions to drive the progression of meiotic prophase I during spermatogenesis.
This mouse study investigated the epigenetic enzyme LSD1 (lysine-specific demethylase 1) during meiotic prophase I in spermatogenesis. Germ cell-specific deletion of Lsd1 caused meiotic arrest at the pachytene stage in primary spermatocytes, leading to infertility. The findings establish LSD1 as a crucial regulator of programmed meiotic progression and provide mechanistic insight into epigenetic causes of male infertility.
Zhu T, Qin S, Dong Y et al. · Journal of genetics and genomics = Yi chuan xue bao · (2026) · View on PubMed ↗
Fertility, pregnancy, and women’s health in bronchiectasis: a multicenter study and ELF-EMBARC patient survey.
This multicenter retrospective cohort study and international patient survey examined fertility characteristics, pregnancy outcomes, and reproductive health experiences in women with bronchiectasis across EMBARC-affiliated centers (pregnancies 2012–2023). The study reports how bronchiectasis affects reproductive outcomes and patient-reported fertility/pregnancy experiences, integrating clinical, pulmonary, obstetric, and neonatal data with survey findings. These results are clinically significant for counseling women of reproductive age with bronchiectasis and for informing future reproductive-health management strategies in this population.
Boehm-Cohen L, Pollock J, Kompatsiari E et al. · Chest · (2026) · View on PubMed ↗
Declining centromere strength compromises meiotic chromosome segregation in aging oocytes.
This study investigated how aging affects meiotic chromosome segregation fidelity in mouse oocytes, focusing on centromere strength and the centromeric proteins CENP-A and CENP-C. It found that aged oocytes show reduced CENP-A and CENP-C levels, with spindle microtubules exhibiting increased misorientation and shorter interaction lengths, and that acute CENP-A degradation during meiosis I destabilizes CENP-C and induces segregation errors even in young oocytes. These findings mechanistically link age-related centromere weakening to aneuploidy risk, identifying centromere component stability as a potential target for preserving oocyte chromosome segregation.
Lemonnier T, Dumont M, Leem J et al. · The Journal of cell biology · (2026) · View on PubMed ↗ · Free PDF ↗
Neuroscience & brain circuitry (imaging, stimulation, neurodegeneration mechanisms)
CX3CL1 (fractalkine)-CX3CR1 interface drives CD8⁺ T cell-induced neurodegeneration in human brain organoids.
This study used human brain organoids to test how the CX3CL1 (fractalkine)–CX3CR1 axis mediates CD8+ T cell–induced neurodegeneration under amyloid-β (Aβ) stress. Aβ increased neuronal CX3CL1, CX3CR1+ CD8+ T cells were recruited toward Aβ-treated organoids via transwell migration, and Aβ also upregulated IL-15 expression, supporting a pro-inflammatory immune-neuron interaction mechanism. These results implicate the CX3CL1–CX3CR1 interface as a driver of T cell–mediated neurodegeneration and a potential therapeutic target in neurodegenerative disease.
Yang WS, Shin MS, Choe MS et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗
Brain Stimulation as a Treatment for Apathy: A Scoping Review of Effects and Safety.
This scoping review evaluated published studies of brain stimulation modalities for treating apathy across diagnostic categories in human patients. Across 52 included studies (with 10 systematic reviews/meta-analyses synthesized separately), the review mapped effects and safety considerations and generated recommendations to guide future research and clinical practice. The work is significant because it consolidates emerging evidence on neuromodulation for a disabling syndrome with limited standardized treatment options.
Grewal P, Seidman MB, Chasen J et al. · The Journal of neuropsychiatry and clinical neurosciences · (2026) · View on PubMed ↗
AKAP2/PKA complex coordinates primary ciliogenesis, ciliary trafficking and Shh signaling.
This mechanistic cell biology study investigated how the AKAP2/PKA complex regulates primary ciliogenesis, ciliary trafficking, and Sonic hedgehog (Shh) signaling. The authors found that AKAP2 dynamically localizes to the primary cilium and forms complexes with kinesin motor proteins and components of the intraflagellar transport (IFT) machinery to coordinate ciliary function. The work is significant because it links a specific signaling scaffold (AKAP2/PKA) to cilium assembly and Shh pathway control, informing potential therapeutic strategies for ciliopathies.
Chiuso F, Giamundo G, Senatore E et al. · Cell communication and signaling : CCS · (2026) · View on PubMed ↗ · Free PDF ↗
Spatiotemporal remodeling in habenula marks the onset of depression-related phenotypes.
This study used spatial transcriptomics and longitudinal in vivo two-photon calcium imaging in male mice to determine when lateral habenula (LHb) molecular and neuronal changes emerge after chronic stress. It revealed topographically organized, temporally defined remodeling of LHb gene expression after chronic stress and showed progressively heightened excitatory neuronal responses to aversive stimuli over time. The results are significant because they define an onset window for depression-related phenotypes, potentially guiding the timing of interventions targeting LHb circuitry.
Molina P, Osypenko D, Garnica J et al. · Nature neuroscience · (2026) · View on PubMed ↗ · Free PDF ↗
Microglia and border-associated macrophages play opposite roles in cerebrovascular and leukocyte responses under systemic inflammation in male mice.
This study assessed how microglia versus border-associated macrophages (BAMs) regulate cerebrovascular function and leukocyte recruitment during sustained systemic inflammation in male mice. Microglia and BAMs had opposite roles: clodronate depletion of BAMs increased leukocyte recruitment, whereas microglia/BAM depletion using PLX5622 or genetic absence of microglia (CSF1RΔFIRE/ΔFIRE) reduced leukocyte recruitment and altered microglia–vascular interactions and cerebral blood flow responses. These results clarify cell-type-specific immune control of neurovascular inflammation and leukocyte trafficking, informing strategies to modulate neuroinflammatory vascular dysfunction.
Brás AR, Lénárt N, Levard D et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗
The Smart MDI System in People With Type 1 Diabetes and High HBA1C: A Randomized Controlled Trial Demonstrating That Response to Alerts Drives Outcomes.
This systems neuroscience study developed Airscope, a 1-gram wireless mesoscope, to perform cortex-wide calcium imaging in naturally behaving mice. Using a wireless link, it enabled cable-free imaging from over 8,500 neurons per animal with 4 μm lateral resolution across a 6 mm field of view at 12.5 Hz. Scientifically, the platform increases throughput and reduces tethering constraints, enabling more comprehensive mapping of distributed cortical circuits during behavior.
Crenier L, Haluzik M, Lind M et al. · Diabetes, obesity & metabolism · (2026) · View on PubMed ↗ · Free PDF ↗
mechanoLight: A genetically encoded fluorescent biosensor for visualizing 5-HT2AR mechanotransduction in live cells.
This study developed mechanoLight, a genetically encoded red fluorescent biosensor engineered by inserting circularly permuted mApple (cp-mApple) into the third intracellular loop of the serotonin 5-HT2A receptor (5-HT2AR) with an optimized linker, to visualize receptor mechanotransduction in live cells. The key finding was that mechanoLight selectively reported 5-HT2AR conformational changes in response to fluid shear stress with minimal sensitivity to 5-HT. This is scientifically significant because it provides a tool to directly image GPCR mechanotransduction dynamics in living cells, enabling mechanistic studies of how mechanical forces are converted into biochemical signaling.
Baek IY, Kim H, Kwon D et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗ · Free PDF ↗
A new reporter strategy reveals a subset of nonmigratory hematopoietic stem cells located in a dynamic bone marrow niche.
This study developed and applied a new double reporter strategy to identify a subset of nonmigratory hematopoietic stem cells (HSCs) within a dynamic bone marrow niche. The key finding was that combining two reporter components improved in situ HSC detection and revealed nonmigratory HSC localization behavior in the bone marrow microenvironment, addressing limitations of prior reporter strategies under perturbed hematopoiesis. This is scientifically important because it refines how HSC niche dynamics are measured, helping resolve contradictory conclusions about HSC migratory behavior.
Secchi MA, Mai C, Liu Q et al. · Blood · (2026) · View on PubMed ↗ · Free PDF ↗
Public health, epidemiology & health economics (vaccines, cost-effectiveness, screening)
Effectiveness of respiratory syncytial virus immunisation in practice.
This real-world evidence review assessed the effectiveness of respiratory syncytial virus (RSV) immunisation strategies across populations affected by severe RSV, including infants and older adults, in routine practice. The key finding is that implemented RSV products show high effectiveness in practice, with emerging benefits extending beyond respiratory outcomes such as reduced cardiovascular events in older adults. These results support broader public-health uptake and inform cost-effectiveness and implementation decisions for RSV prevention.
Groenendijk RW, Franck Z, Baral R et al. · The Lancet. Infectious diseases · (2026) · View on PubMed ↗
Placebo effects of caffeine on sport performance: a systematic review and meta-analysis.
This systematic review and meta-analysis synthesized evidence on deceptive placebo effects when caffeine is described as caffeine on sport performance in healthy adults. Across 17 included studies, the authors estimated standardized mean differences for performance outcomes and assessed study quality using Cochrane risk-of-bias criteria, with many studies judged high risk or unclear (results truncated). The findings quantify how expectancy-driven “placebo caffeine” effects may influence athletic performance and inform interpretation of caffeine trials.
Hurst P, Hanssen J, Marticorena F et al. · Journal of the International Society of Sports Nutrition · (2026) · View on PubMed ↗ · Free PDF ↗
Exome-wide association study reveals common and rare coding variants shaping chronic pain in 327,642 UK biobank participants.
This exome-wide association study used whole-exome sequencing in 327,642 European participants from the UK Biobank to identify common and rare coding variants associated with chronic pain across ten pain phenotypes. The study performed variant-level and gene-level association analyses to uncover coding signals contributing to chronic pain susceptibility and shared genetic architecture across phenotypes. The findings are clinically important because they refine the genetic basis of chronic pain and may highlight biological mechanisms for future risk prediction and therapeutic targeting.
Ao X, Kolifarhood G, Parisien M et al. · Genome medicine · (2026) · View on PubMed ↗ · Free PDF ↗
Projected Effect of 2026 Federal Changes to the Childhood Immunization Schedule on Chronic Hepatitis B Virus Infections in the United States.
This modeling study used a Markov cohort state transition approach to project how proposed 2026 changes to the U.S. childhood hepatitis B virus (HBV) immunization schedule would affect chronic HBV infections. The key finding is the projected impact of different vaccination strategies (universal birth-dose, deferred, and shared decision-making) on chronic HBV infection burden in a one-year U.S.-born infant cohort. This is significant for public health planning because it quantifies how policy changes could alter long-term HBV transmission and chronic infection rates.
Mohareb AM, Ganapathi L, Dugdale CM et al. · Annals of internal medicine · (2026) · View on PubMed ↗
Lessons learned from the COVID-19 pandemic for future cochlear implant service preparedness: a multicenter study.
This multicenter retrospective comparative study assessed cochlear implant (CI) service preparedness by analyzing CI service delivery across seven centers in Bahrain and Saudi Arabia before versus during the COVID-19 pandemic. The key finding was that the pandemic disrupted CI workflows and access, with measurable changes in procedural volumes, waiting lists, and related service metrics compared with the pre-pandemic period. This is significant for future public health planning because it identifies operational vulnerabilities that could delay pediatric CI and thereby affect auditory and language development.
Alshehabi M, Elakkawi S, Alzahrani M et al. · Cochlear implants international · (2026) · View on PubMed ↗
Mortality Among People With Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis.
This systematic review and meta-analysis examined whether ADHD is associated with all-cause and cause-specific mortality and whether mortality risk differs by ADHD medication use, using international data searched through July 8, 2025. The abstract truncation does not include the pooled effect estimates, but the study’s goal was to quantify mortality risk and evaluate potential associations with ADHD pharmacotherapy. Clinically, the findings are intended to inform risk communication, medication decision-making, and public health strategies for ADHD.
Corrigan L, Heywood L, Stewart GR et al. · JAMA network open · (2026) · View on PubMed ↗ · Free PDF ↗
Vascular Risk Factors and Late-Onset Epilepsy.
This individual participant data meta-analysis investigated vascular risk factors for incident late-onset epilepsy (LOE; onset ≥65 years) using 6 US population-based prospective cohorts with Medicare linkage for epilepsy ascertainment. The study design begins LOE follow-up after participants accrue 2 years of continuous fee-for-service enrollment and are ≥65, enabling assessment of which vascular risk factors predict LOE. If vascular associations are identified, they could support prevention strategies targeting vascular risk to reduce LOE incidence in older adults.
Choi H, Gutierrez J, Wang T et al. · JAMA neurology · (2026) · View on PubMed ↗
Time trends of human papillomavirus-attributable head and neck cancers: the BROADEN study.
This retrospective BROADEN study assessed time trends in human papillomavirus (HPV)-attributable fractions for head and neck cancers (HNC) across multiple countries, including France, Germany, Italy, Portugal, Spain, China, and Japan. It compared HPV-AFs between two diagnostic periods (2008–2009 vs 2018–2019) using centrally tested formalin-fixed tissue samples for cancers spanning oropharynx, oral cavity, nasopharynx, hypopharynx, and larynx. The significance is improved understanding of how HPV-driven cancer burden is changing geographically and by cancer site, informing prevention and screening strategies.
Waterboer T, Zhao F, Giuliano A et al. · Journal of the National Cancer Institute · (2026) · View on PubMed ↗ · Free PDF ↗
Cost-effectiveness of monotherapy and combination therapy for myopia control in Chinese children.
This study evaluated the cost-effectiveness of myopia control monotherapy versus combination therapy in Chinese children and adolescents aged 6–18 years using a network meta-analysis and a decision-analytic Markov model. It found that different myopia-control strategies can be compared economically over an 8-year horizon using axial length (AL) and spherical equivalent refraction (SER) changes as primary efficacy outcomes, informing which combinations may provide better value for money in China. The results are scientifically and policy significant because they support evidence-based selection of myopia interventions to reduce long-term progression while considering healthcare costs.
Wang J, Li X, He M et al. · Journal of global health · (2026) · View on PubMed ↗ · Free PDF ↗
Clinical trials & perioperative/rehab interventions (surgery, radiotherapy, devices, pain)
Individualized Cardiac Index-Guided Hemodynamic Therapy in High-Risk Patients Undergoing Elective Major Abdominal Surgery: The PELICAN Randomized Clinical Trial.
This multicenter, single-blind, superiority randomized clinical trial evaluated whether individualized cardiac index-guided intraoperative hemodynamic therapy improves outcomes versus routine hemodynamic therapy in high-risk patients undergoing elective major abdominal surgery. The key finding is the trial’s assessment of outcome differences attributable to cardiac index-guided management (details truncated in the provided abstract). This is clinically significant because it tests whether cardiac index targeting should guide intraoperative hemodynamic treatment to improve perioperative outcomes in high-risk surgical patients.
Saugel B, Meidert AS, Meyhoff CS et al. · JAMA · (2026) · View on PubMed ↗
Hypofractionated Versus Conventionally Fractionated Postmastectomy Radiotherapy With Internal Mammary Node Irradiation for High-Risk Breast Cancer (HypoMast-IMNI): A Randomized Phase III Trial.
This randomized phase III noninferiority trial studied hypofractionated postmastectomy radiotherapy (HypoRT; 42.56 Gy/16 fractions) versus conventional fractionation (ConvRT; 50 Gy/25 fractions), both including internal mammary node irradiation (IMNI), in high-risk operable breast cancer patients after mastectomy. The key finding was the trial’s evaluation of whether HypoRT is noninferior to ConvRT for efficacy and safety when internal mammary nodes are targeted. If noninferiority is confirmed, this would be scientifically and clinically important because it could support shorter, more convenient PMRT regimens with IMN coverage for high-risk patients.
Wang X, Zhang X, Chen X et al. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · (2026) · View on PubMed ↗ · Free PDF ↗
Updated recommendations for osteoporosis treatment according to fracture risk: 2026 revision by the Swiss Association against Osteoporosis (SVGO).
This article provides updated Swiss Association against Osteoporosis (SVGO) recommendations for osteoporosis treatment based on fracture risk, revising the 2020 risk-based framework. The key finding is the integration of advances in fracture-risk assessment (including Swiss FRAX probabilities and possible FRAXplus refinement), lifestyle management, anabolic therapy, treatment sequencing, and treat-to-target concepts into five risk categories (low to imminent risk). This is clinically significant because it standardizes risk-stratified treatment decisions in Switzerland, particularly emphasizing anabolic-first strategies for patients at imminent or very high risk.
Ferrari S, Biver E, Gonzalez-Rodriguez E et al. · Swiss medical weekly · (2026) · View on PubMed ↗ · Free PDF ↗
Efficacy of Saffron as an Adjunct to Methylphenidate in Treating ADHD in Children Aged 6-12: A Randomized Clinical Trial.
In a randomized clinical trial, 58 children aged 6–12 years with ADHD were assigned to methylphenidate plus saffron extract versus methylphenidate alone to assess ADHD symptom severity and working memory. The abstract truncation does not provide the numerical results, but the study was designed to test whether saffron adjunct therapy improves outcomes beyond methylphenidate. If positive, this would support a potential adjunct strategy for children who have incomplete response or tolerability issues with methylphenidate.
Hosseinpourfardi A, Sahaf SMS, Afzaljavan F et al. · Brain and behavior · (2026) · View on PubMed ↗ · Free PDF ↗
Generated automatically on October 21, 2026 from PubMed’s trending articles. Summaries are AI-generated; always consult the original publication for clinical or research decisions.